XERIS BIOPHARMA HOLDINGS INC

XERS is the ticker symbol for Xeris Biopharma Holdings, Inc., a biopharmaceutical company. It trades on the Nasdaq stock exchange. The company focuses on developing and commercializing injectable and non-aqueous formulations of drugs. As a publicly traded stock, XERS represents an ownership stake in the company and its pipeline of therapies.

Recent performance for XERS stock can be found in the price and performance section of this page, which shows the latest price, daily change, and historical trends. Performance depends on factors like clinical trial results, regulatory decisions, and financial reports. For up-to-date figures, refer to the data displayed on this page.

Evaluating XERS valuation involves examining metrics such as market capitalization, price-to-sales ratio, and enterprise value, especially since the company may not have consistent earnings. Comparing these metrics to peers in the biopharmaceutical industry and considering the company's pipeline potential can provide context. Current valuation data is available on this page.

XERS stock can be traded in pre-market and after-hours sessions through many brokerage platforms, though liquidity may be lower and spreads wider than during regular trading hours. Extended-hours trading carries additional risks, such as reduced volume and higher volatility. Check with your broker for specific availability and hours.

Earnings information for XERS, including quarterly reports, revenue, and net income, is typically available in the investor relations section of the company's website and in SEC filings such as 10-Q and 10-K reports. Financial news platforms and the earnings section of this page may also summarize key figures. These reports provide details on the company's financial performance.

Investing in XERS carries risks common to biopharmaceutical companies, such as clinical trial failures, regulatory hurdles, and reliance on successful commercialization of products. Financial risks include potential dilution, cash burn, and competition. Additionally, market volatility and broader economic conditions can affect the stock price. Investors should review the company's risk factors in its SEC filings.